Zoledronic acid Completed Phase 2 Trials for Osteogenesis Imperfecta (OI) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00131118Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
NCT00063479Bisphosphonate Treatment of Osteogenesis Imperfecta